This video was originally uploaded in September 2017.

Marie shares her reaction to being diagnosed with metastatic breast cancer.

Η Μαρή μοιράζετε την αντίδραση που είχε στη διάγνωση με μεταστατικό καρκίνο του μαστού.

Cristina Saura Manich, MD, PhD, Vall d'Hebron Institute of Oncology, Barcelona, Spain, outlines how current treatments for patients with HER2-positive metastatic breast cancer will change in the future. The DESTINY-Breast03 study (NCT03529110) demonstrated a significant benefit for patients with HER-2 positive metastatic disease treated with trastuzumab deruxtecan (T-DXd) over patients treated with trastuzumab emtansine (T-DM1). The approval of T-Dxd for this patient population will change clinical practice. In addition, novel agents including margetuximab and new antibody-drug conjugates (ADCs) will soon be approved and added to the current treatment strategies consisting of combinations of chemotherapy, trastuzumab, and tyrosine kinase inhibitors (TKIs). Dr Saura Manich emphasizes the need to investigate mechanisms of resistance to these drugs and explore the best sequencing strategies. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

Michael Knauer, PhD, FEBS, Breast Center Ostschweiz AG, St. Gallen, Switzerland, outlines the role of surgery in metastatic breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

In her third video, Jeanne shares more details about the events leading up to her diagnosis, and what she decided to do after getting the news. “I just through all of it kept thinking to myself ...I just want this all to be over with so I can get back to my normal life, and God had other plans for me because I didn’t get back to my normal life.”

Women are now able to live longer, fuller lives despite metastatic breast cancer, which means the disease has spread outside the breast.

Metastatic Breast Cancer